Literature DB >> 28334467

Revisiting the 'paradigm shift' in opioid use: Developments and implications 10 years later.

Benedikt Fischer1,2,3, Jürgen Rehm1,2,4,5,6.   

Abstract

A decade ago, we queried the unfolding of a 'paradigm shift' in illicit opioid use in North America, specifically involving a shift away from heroin to prescription opioid (PO) use. Today, this situation is more acute than ever, with prescription opioid misuse, morbidity and mortality amounting to one of the most severe substance use-related public health crises ever, now even impacting life expectancy in key population segments. Despite medical system-based PO dispensing and practices being recognised as core drivers of the PO crisis, effective policy measures have been long absent or limited-including those to reduce medical PO use to levels supported by best evidence for pain care. At the same time, heroin use has been increasing again, now commonly tied into interdependent opioid use trajectories, initiated with POs yet shifting to heroin as influenced by economic or availability factors. For policy, there are now two major and urgent-yet partly conflicting-tasks: one is to reduce the determinants of PO misuse and harms by reducing medical prescribing to levels supported by good evidence, while the other is to effectively protect those many active problematic PO users from acute harms (including overdose mortality) by providing effective treatment and survival aids (e.g. naloxone). Surprisingly, it appears that a major 'homemade' and medical system-induced drug crisis has been at least as challenging for North American policy systems to address as other, more conventional illicit drug problems. Lessons for policy hence need to be urgently identified and applied for the future. [Fischer B, Rehm J. Revisiting the 'paradigm shift' in opioid use: Developments and implications 10 years later. Drug Alcohol Rev 2017;00:000-000].
© 2017 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  burden of disease; epidemiology; heroin; prescription opioids; public health

Mesh:

Substances:

Year:  2017        PMID: 28334467     DOI: 10.1111/dar.12539

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  7 in total

1.  New Canadian guidance on opioid use for chronic pain: necessary but not sufficient.

Authors:  Andrea D Furlan; Owen D Williamson
Journal:  CMAJ       Date:  2017-05-08       Impact factor: 8.262

2.  Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an 'index' for monitoring and evaluation.

Authors:  Benedikt Fischer; Cayley Russell; Jürgen Rehm; Pamela Leece
Journal:  J Public Health (Oxf)       Date:  2019-06-01       Impact factor: 2.341

3.  Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps.

Authors:  Benedikt Fischer; Michelle Pang; Mark Tyndall
Journal:  J Public Health (Oxf)       Date:  2020-11-23       Impact factor: 2.341

Review 4.  The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?

Authors:  Stine Bordier Høj; Nanor Minoyan; Andreea Adelina Artenie; Jason Grebely; Julie Bruneau
Journal:  Can Liver J       Date:  2018-07-17

5.  Current perspectives on the opioid crisis in the US healthcare system: A comprehensive literature review.

Authors:  Nicoleta Stoicea; Andrew Costa; Luis Periel; Alberto Uribe; Tristan Weaver; Sergio D Bergese
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 6.  Lessons learned from the opioid crisis across the pillars of the Canadian drugs and substances strategy.

Authors:  Sheena Taha; Bridget Maloney-Hall; Jane Buxton
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-08-19

7.  Opioid Epidemic in the United States: Empirical Trends, and A Literature Review of Social Determinants and Epidemiological, Pain Management, and Treatment Patterns.

Authors:  Gopal K Singh; Isaac E Kim; Mehrete Girmay; Chrisp Perry; Gem P Daus; Ivy P Vedamuthu; Andrew A De Los Reyes; Christine T Ramey; Elijah K Martin; Michelle Allender
Journal:  Int J MCH AIDS       Date:  2019-08-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.